Establishing relationships between particle-induced in vitro and in vivo inflammation endpoints to better extrapolate between in vitro markers and in vivo fibrosis

Keyphrases

• Fibrosis 100%
• In Vivo Inflammation 100%
• New Approach Methodologies 100%
• Cytokine Secretion 66%
• Crystalline Silica 66%
• Testing Strategy 66%
• Pulmonary Fibrosis 66%
• Interleukin-6 33%
• Adverse Outcomes 33%
• Silica 33%
• Dose-response Curve 33%
• Risk Assessment 33%
• Regulatory Purposes 33%
• In Vitro Techniques 33%
• Conversion Factor 33%
• Adverse Outcome Pathway 33%
• Toxicity Assessment 33%
• Dose-response 33%
• Screening Tool 33%
• Product Development 33%
• Computational Tools 33%
• Lung Inflammation 33%
• IL-1 Family Cytokines 33%
• Polymorphonuclear Leukocytes 33%
• Leukocyte Recruitment 33%
• Cerium Oxide Nanoparticles 33%
• In Vivo Methods 33%
• Acute Lung Inflammation 33%
• Hazard Information 33%
• In Vivo Dosimetry 33%
• Nano-CeO2 33%
• High-throughput in Vitro Model 33%
• Five Steps 33%
• Quantitative Adverse Outcome Pathway 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Silicon Dioxide 100%
• Inflammation 100%
• Fibrosis 100%
• Adverse Outcome Pathway 66%
• Lung Fibrosis 66%
• Cytokine 66%
• Pneumonia 66%
• Toxicity Assessment 33%
• Dosimetry 33%
• Adverse Outcome 33%
• Cerium Oxide Nanoparticle 33%